NCT01923116View on ClinicalTrials.gov

Therapeutic HPV-16 Vaccination for the Treatment of Anal Dysplasia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

June 30, 2017

Study Completion Date

December 31, 2017

Conditions
Anal Intraepithelial NeoplasiaHIV
Interventions
DRUG

HPV-16 vaccine

Vaccination with SLP-HPV-01® with or without interferon-a injections.

Trial Locations (1)

1105 AZ

Academic Medical Center, Amsterdam

Sponsors

Collaborators (1)

ISA Pharmaceuticals B.V.
All Listed Sponsors
collaborator

Leiden University Medical Center

OTHER

collaborator

ISA Pharmaceuticals B.V.

INDUSTRY

lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

NCT01923116 - Therapeutic HPV-16 Vaccination for the Treatment of Anal Dysplasia | Biotech Hunter | Biotech Hunter